Pragmatic Approaches to Drug Safety Across the Premarketing and Postmarketing Continuum

Back to Agenda

Session 16: Group Exercise II: Monitoring Development of a Novel Anti-Psychotic Product

Session Chair(s)

JP Clement, MD

Founder and Principal

JPCC Associates, United States

A clinical monitoring scenario involving pharmacokinetics of a novel anti-psychotic product will be presented for discussion in small groups. All groups will share their considerations for actions and next steps with all participants.

Have an account?

Pragmatic Approaches to Drug Safety Across the Premarketing and Postmarketing Continuum

Session 16: Group Exercise II: Monitoring Development of a Novel Anti-Psychotic Product

Session Chair(s)

JP Clement, MD

Be informed and stay engaged.